Next Article in Journal
Association between Clinical Manifestations in Temporomandibular Joint Disorders and Corresponding Radiographic Findings
Previous Article in Journal
Nationwide Trends in Hospitalizations for Atrial Fibrillation and Flutter in the United States before and during the Outbreak of the COVID-19 Pandemic
Previous Article in Special Issue
Patients with Type 2 Diabetes, Higher Blood Pressure, and Infrequent Fundus Examinations Have a Higher Risk of Sight-Threatening Retinopathy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 13
Issue 16
10.3390/jcm13164884
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hyperuricaemia Prevalence Rates According to Their Physiochemical and Epidemiological Diagnostic Criteria and Their Associations with Cardio-Renal-Metabolic Factors: SIMETAP-HU Study

by
Antonio Ruiz-García
1,2,†,
Adalberto Serrano-Cumplido
3,†,
Ezequiel Arranz-Martínez
4,
Carlos Escobar-Cervantes
5 and
Vicente Pallarés-Carratalá
6,*
1
Lipids and Cardiovascular Prevention Unit, Pinto University Health Centre, 28320 Madrid, Spain
2
Department of Medicine, European University of Madrid, 28005 Madrid, Spain
3
Repelega Health Centre, 48920 Portugalete, Spain
4
San Blas Health Centre, 28981 Madrid, Spain
5
Department of Cardiology, La Paz University Hospital, 28046 Madrid, Spain
6
Department of Medicine, Jaume I University, 12006 Castellon, Spain
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Clin. Med. 2024, 13(16), 4884; https://doi.org/10.3390/jcm13164884
Submission received: 16 July 2024 / Revised: 13 August 2024 / Accepted: 15 August 2024 / Published: 19 August 2024
(This article belongs to the Special Issue Pathophysiology of Hypertension and Related Diseases)
Browse Figures
Versions Notes

Abstract

:
Background: Scientific societies disagree on serum uric acid (SUA) thresholds for the diagnosis of hyperuricaemia (HU) according to epidemiological or physiochemical criteria (SUA ≥ 7.0 mg/dL for men and ≥6.0 mg/dL for women [HU-7/6]; SUA ≥ 7.0 mg/dL for both genders [HU-7/7], respectively). HU is not included among the diagnostic criteria for metabolic syndrome or cardiovascular-renal-metabolic syndrome (CKM), although it promotes atherosclerosis and is associated with renal and cardiometabolic diseases. Both issues are of utmost importance and need to be clarified, hence the present study aims to assess the prevalence rates of HU and their associations with CKM factors. Methods: A cross-sectional observational study was conducted on a random population-based sample of 6489 adults. Bivariate and multivariate analyses were performed on the most well-known renal and cardiometabolic variables of the populations with and without HU-7/7 and HU-7/6. Results: The adjusted prevalence rates for HU-7/6 were 13.4% in adult population (18.4% in men; 9.6% in women) and 10.2% (18.4% in men; 3.8% in women) for HU-7/7. The main factors associated independently with HU for both genders were low estimated glomerular filtration rate, hypertension, hypertriglyceridaemia, and alcoholism, regardless of the criteria chosen, as well as albuminuria in women and central obesity in men. Conclusions: The prevalence rates of HU increase linearly with age for both genders. The associations of CKM factors with HU diagnosed according to physiochemical criterion are more similar between men and women than those using epidemiological criteria.

1. Introduction

International scientific societies disagree on serum uric acid (SUA) thresholds and a single definition for the diagnosis of hyperuricaemia (HU). Some societies [1,2] rely on epidemiological criteria based on the higher average concentrations of SUA in the male population (7.0 mg/dL) than in the female population (6.0 mg/dL) according to an old conference held in Rome in 1961 [1]. Other societies [3,4,5,6] argue that the HU concept should be based on a single pathogenic physiochemical criterion related to the plasma crystallization threshold of monosodium urate (MSU) [3,4,5,6], which occurs without distinction of gender from SUA concentrations around 7 mg/dL [7]. This discrepancy in the diagnosis of HU favours the high variability of the prevalence rates reported for HU and greatly hinders the real assessment of the burden of the disease.
HU is the increase in SUA concentration due to a purine metabolic disorder caused by an imbalance between the increase in uric acid production and the decrease in its elimination, mainly through renal excretion. HU stimulates the production of acute-phase pro-inflammatory molecules that promote the complex process of the pathogenesis of atherosclerosis [8], and it is associated with increased incidence of type 2 diabetes mellitus (DM) [9], metabolic syndrome (MetS) [10], arterial hypertension (HTN) [11,12], cardiovascular diseases (CVD) [13,14,15,16], heart failure (HF) [17], atrial fibrillation (AF) [18], and chronic kidney disease (CKD) [19]. The complexity of the MetS pathogenesis involves different organs and causes predisposition to many diseases. A recent study showed some significant relationships in euthyroid subjects between thyroid volume and function and the results of anthropometric parameters, body composition, and the presence of MetS features [20]. Dysfunction and/or an excess of adipose tissue also promotes the secretion of pro-inflammatory and pro-oxidant molecules that decrease insulin sensitivity, leading to multi-organ damage and promoting the development of multiple clinical disorders and diseases. The consequence of this process is the new so-called cardiovascular–kidney–metabolic (CKM) syndrome, which is defined as a systemic disorder attributable to the pathophysiological interactions between the aforementioned clinical conditions [21].
Cardiometabolic and renal diseases are the most important health disorders worldwide. Their high prevalence rates constitute a public health emergency, not only because the high health care expenditures they cause, but also due to a potential increased risk of premature mortality, a significant clinical implication, and a large burden of cardiovascular disease caused by this excess morbidity [21].
A critically important issue is that HU is not included among the diagnostic criteria for MetS [22] or CKM syndrome [21], despite the fact that it is a disorder that patients with cardiometabolic diseases frequently suffer from, promotes atherosclerosis, and is associated with cardiometabolic diseases.
Both issues are of the utmost importance and need to be clarified. Hence, the present study aims to update and compare the prevalence rates of HU in Spanish adults according to the two aforementioned diagnostic criteria of HU and to evaluate their associations with renal and cardiometabolic factors.

2. Materials and Methods

2.1. Study Design

This is a multicentre cross-sectional observational sub-study from the SIMETAP study, the design and methodology of which has been reported elsewhere [23], authorised by the Community of Madrid Health Service (Spain) and conducted by 121 physicians from 64 primary healthcare centres. Briefly, all people aged 18 years or older assigned by the Madrid Health Service to research physicians were included for recruitment in a simple random sampling performed by the Excel’s randbetween function. Inclusion criteria: The order indicated by the lists of random numbers was applied to include the study subjects until reaching the sample size necessary to evaluate the objectives of the study. Patients with terminal illnesses or cognitive impairment; institutionalised people; those with dementia, schizophrenia, or moderate or severe psychosis; residents of nursing homes; pregnant women; and people who were participating in other clinical studies were excluded per protocol. Finally, 6489 adults between 18.0 and 102.8 years of age were included in the study, with informed consent and with the necessary clinical and laboratory data to be evaluated (response rate 61.9%). All information assessed in our study was collected from the primary care electronic health records under a real-world data setting.

2.2. Definitions of HU, Medical Conditions and Comorbidities

The physiochemical criterion of SUA concentrations determined by the uricase laboratory method ≥ 7.0 mg/dL (416 µmol/L) was considered the primary definition of HU (HU-7/7) for both men and women [3,4,5,6]. Furthermore, we assessed the epidemiological definition (HU-7/6) [1,2] if the SUA concentrations were ≥7.0 mg/dL (HU-7) for men and ≥6.0 mg/dL (357 µmol/L) (HU-6) for women. For both definitions, we also considered HU if the patients were on urate-lowering drug therapy (ULT). The criteria defining CKM syndrome [21] and other comorbidities or medical conditions are reported in Table S1 (Supplementary Materials).

2.3. Statistical Analysis

The age- and sex-adjusted prevalence rates were calculated by the direct method according to Spanish population data of the Spanish National Institute of Statistics. Median and interquartile range (IQR) of age of study population were determined. Qualitative variables indicated the number and percentage of each category, using Chi-square test and odds ratios (OR), with a 95% confidence interval (CI). The Shapiro–Wilk test was used to check the data fitting to normal distribution for continuous variables. If the variables showed normal distribution, they were analysed using the arithmetic mean and standard deviation (SD) and compared using Student’s t-test or analysis of variance. Cohen’s d was used to assess the standardised mean difference, considering the effect size according to the proximity to the following d-values: 0.2, small; 0.5, medium; 0.8, large. Bivariate and multivariate analysis were performed in both male and female populations with HU-7 and in the female population with HU-6. To assess the individual effects of comorbidities and clinical conditions on the dependent variables (HU-7/7; HU-7/6), multivariate logistic regression analysis was performed using the backward stepwise method, initially introducing into the model all the variables that showed an association in the bivariate analysis up to a p-value < 0.10, except those complex variables with parameters evaluated individually in the analysis. Subsequently, the variable that contributed least to the fit of the analysis was eliminated at each step. All tests were considered statistically significant if the two-tailed p-value was <0.05. Statistical analysis was performed using the SPSS for Windows, version 25 (IBM, Armonk, NY, USA).

3. Results

3.1. General Clinical Characteristics of Overall Study Population

Women represented 56.0% of the study population. Most clinical characteristics were significantly higher in men than in women (Table S2 Supplementary Materials). The median (IQR) ages were 55.0 (42.4–67.5) years in men and 54.5 (41.1–68.8) years in women. The median (IQR) of SUA were 5.6 (4.7–6.6) mg/dL in men and 4.2 (3.5–5.1) mg/dL in women, concentrations very similar to their respective means of SUA, and whose distributions followed Gaussian curves. The mean SUA was 1.31 mg/dL (95% CI: 1.24–1.38) (78 µmol/L) higher in men than in women (p < 0.001) (Figure S1 Supplementary Materials).

3.2. HU Prevalence Rates

The crude and adjusted prevalence rates for all study population and according to sex- and age-groups are shown in Table 1. Distributions of age-specific prevalence rates for population with HU-7/7 and for population with HU-7/6 increased quasi-perfectly with age according to linear functions (Figure 1A,B, respectively), being significantly higher in men for all age-groups, except those aged over 70 years for HU-7/6. In patients with HU, the ULT was used in 15.2% of overall population, 20.0% in men, and 13.2% in women (OR 4.2 [95% CI: 2.6–6.8]). Daily doses of ULT ranged between 100 and 300 mg of allopurinol, except one patient who took 100 mg of benzbromarone daily.

3.3. Clinical Characteristics of Study Subjects According to Both Diagnostic Criteria

The mean [SD] ages of women with HU-7 (67.5 [15.8] years) and with HU-6 (67.3 [15.4] years) were similarly higher (8.4 and 8.1 years, respectively) and significantly older than those of men (p < 0.001). In both male and female populations, most clinical characteristics were significantly higher in HU than non-HU populations. On the contrary, high-density lipoprotein cholesterol and the estimated glomerular filtrate ratio (eGFR) were significantly lower in HU than in non-HU populations. Differences in low-density lipoprotein cholesterol (LDL-C) and aspartate aminotransferase between HU and non-HU populations were non-significant in both male and female populations. Likewise, differences in fasting plasma glucose and glycated haemoglobin A1c were non-significant in the male population, and total cholesterol was non-significant in female populations. According to both physiochemical and epidemiological criteria, the effect sizes according to Cohen’s d-values of the standardised mean difference between the HU and non-HU populations were similar among women, and were also larger in women than in men (Table 2).

3.4. Effect of CKM Factors and Medical Conditions on HU

All factors and medical conditions of CKM syndrome were associated with HU according to both criteria, except the variable of physical inactivity according to the physiochemical criterion and overweight according to the epidemiological criteria (Figure 2, Table S3). It is worth mentioning that only 21 patients were on ULT and that they were the same study subjects included in the group diagnosed according to the epidemiological criteria according to the physiochemical criterion. The OR values were very similar when comparing the factors and medical conditions of CKM syndrome, both between the female population with HU-6 and the male population with HU-7 and between both populations with HU-7 (Table S4, Supplementary Materials). Figure 3 shows the graphs of the multivariate analysis of the CKM factors and the medical conditions that are independently associated with HU-7/7 and HU-7/6, both for the general population and according to sex. The most important CKM factors that appear in all the graphs are low eGFR, HTN, and hypertriglyceridaemia (HTG). Likewise, alcoholism appears in all the graphs as a factor independently associated with HU according to both criteria. Figure 4 shows the prevalence rates of the independent factors associated with HU-7/7 and HU-7/6 according to sex, which also include central obesity according to both diagnostic criteria, obesity according to epidemiological criteria, and albuminuria according to the physiochemical criterion.

4. Discussion

4.1. Hyperuricaemia Prevalence Rates

Average SUA concentrations vary among ethnicities and countries [24], differ by more than 1 mg/dL between men and women, and increase linearly with age in both genders, as we also show in our study.
There is a lack of consensus to define HU, which makes it difficult to compare studies [25]. Some epidemiological prevalence studies define HU as SUA above 6 mg/dL [26,27]. These different criteria may cause the variability in HU prevalence rates to be exaggeratedly high, ranging from 1% in Papua New Guinea to 52% in Taiwan, with variations even in the same countries according to sex or ethnic origin [28]. Other authors [29] and guidelines [1,2] prefer to use two SUA cut-off points to diagnose HU (>7 mg/dL in male; >6 mg/dL in female), arguing epidemiological criteria, because the difference in the HU prevalence rates between the male and female population is too large, as shown in population-based studies carried out in Japan [30]. We consider the mean difference in SUA of 1.0 mg/dL (59 µmol/L) between men and women used for the epidemiological definition of HU to be an easy number to remember, but approximately 25% lower than real-world data, as we report in our study (1.3 mg/dL [78 µmol/L]). Furthermore, the epidemiological cut-off point > 6 mg/dL for females lacks pathogenic relevance for MSU crystals formation. In accordance with the recommendations of clinical guidelines [3,4,5,6], the HU definition should be established in physiochemical terms as the presence of SUA levels above the saturation point for crystallization of MSU (above 6.8 mg/dL) [7], which is unique in humans, regardless of sex. Therefore, herein, we primarily support the definition of HU according to the physiochemical criterion for both genders.
According to the NHANES database from the United States, the prevalence of HU was 20.1% (20.2% in men [with SUA > 7.0 mg/dL]; 20.0% in women [with SUA > 5.7 mg/dL]), or 11.9% (20.2% in male; 4.2% in female) for HU-7/7 [31]. In our study, the HU-7/7 crude prevalence rates were very similar. In a younger Italian population (mean age 43 years), the HU-7/6 prevalence rates were lower (7.3% in men; 2.8% in women) and higher (37.3% and 4.7%, respectively) when 5.6 mg/dL was considered as the cut-off point in both sexes [32]. The HU-7/6 crude prevalence rates of our overall adult population (15.2%) were similar to those detected in the cohort of Spanish patients (mean age 58.7 years) from IBERICAN study [33] (16.3%), although they were higher in men (20.3% vs. 18.7%) and lower in women (11.2% vs. 14.1%), probably due to a slightly lower mean age of our study subjects (55.2 years) and the different sample designs (population-based vs. consecutive recruitment from primary care practices, respectively). The HU-7/6 adjusted prevalence rates of our study were very similar to those found in China (13.5% in adults; 17.3% in males; 10.0% in females) [34].

4.2. CKM Factors and Medical Conditions Associated with HU

Body fat distribution is a better risk predictor of comorbidity than obesity determined by waist circumference or body mass index [35]. Furthermore, high WtHR levels are associated with an increased risk of atherosclerotic cardiovascular disease and all-cause mortality [36]. A study carried out in Japan showed that HU was associated with central obesity (WtHR ≥ 0.5), with greater intensity when there was excess weight, but also in the absence of excess weight [37]. We assessed central obesity and adiposity using the WtHR [38] and the CUN-BAE (according to its acronym in Spanish, Clínica Universitaria de Navarra—Body Adiposity Estimator) index [39], respectively, and found that these predictors were more strongly associated with HU (according to both diagnostic criteria) than the obesity, especially in women. Neither overweight nor obesity appeared as independent factors for HU-7 in males in the multivariate analysis. However, central obesity was an independent risk factor for HU-7 in men, and for HU-6 in women. Therefore, central obesity should be identified in HU patients regardless of the existence of excess weight.
The ethanol consumption in alcoholic beverages is the main dietary risk factor contributing to HU, increasing uric acid production and decreasing its renal elimination [40]. Our study showed that alcoholism is an independent risk factor for HU, with a greater association in women than in men for the epidemiological diagnostic criteria, and an even stronger association in females for the physiochemical diagnostic criterion.
Many studies have reported that HU is associated with CVD [13,14,15,16], HF [17], AF [18], and CKD [19], in addition to risk factors such as HTN [11,12], DM [9], MetS [10], HTG, and high LDL-C levels [41]. Our study showed no association between total cholesterol, LDL-C, or peripheral artery disease and HU. No association was found between glycaemic parameters, DM, coronary heart disease, stroke, or AF and male HU, and, on the contrary, these variables did show an association with female HU, probably favoured by the greater age difference with the respective populations without HU (13.0 years in women; 4.9 years in men). HF was associated with HU in both men and women, although it did not appear as an independent risk factor for HU in the multivariate analysis. On the contrary, HTG did appear as an independent risk factor for HU in both genders.
Some authors reported that HU was an independent risk factor for HTN [11,12] and that this relationship was stronger in females than in males [12]. Our study confirmed that HTN is the second strongest independent risk factor for HU, and that the association between HTN and HU is closer in females than in males for HU-7/6, and even stronger for HU-7/7.
There is a close relationship between HU and MetS [10]. Our study showed a risk of MetS almost three times higher in women than in men. This difference may be due to the greater susceptibility of women to the MetS risk, with lower SUA levels [42]. New insights into pathophysiology of MetS has risen by assessing the involvement of other emerging risk factors such as HU [43]. Our study shows a high prevalence of MetS, CKD, HF, AF, and CVD in patients with HU, which leads us to suspect that CKM syndrome is even more common in them. On the other hand, the metabolic dysfunction-associated steatotic liver disease (SLD) and its possible evolution to more serious liver and cardiovascular diseases is known [44]. In our study, FLI ≥ 60, an accurate predictor of SLD [45], was the factor that was more strongly associated in the female population with HU-7 and HU-6 than in males with HU-7, which could support the close relationship between HU and SLD. Two-thirds of study subjects with HU-7/7 had FLI ≥ 60; therefore, they were more likely to suffer from SLD. Early evaluation of the degree of liver involvement would help in the early application of preventive behaviours and appropriate therapies.
Approximately 70% of SUA is excreted through the kidneys; hence, SUA levels are associated with CKD progression by increasing with the eGFR decrease [19]. Our study also showed stronger associations between HU and CKD, low eGFR, and albuminuria in women than in men according to both criteria, being tighter when the physiochemical criterion was used. Of note, multivariate analysis showed that albuminuria appeared as a factor independently associated with HU in women according to the physiochemical criterion and that it disappeared according to the epidemiological criteria.
HU is a marker that can increase cardiovascular risk (CVR) [46]. However, the optimal value of SUA from which the CKM risk increases has yet to be determined [47]. Our study showed that the percentage of subjects with very high CVR is greater in women than in men, using both the physiochemical and epidemiological criteria.
It is noteworthy that only 21 patients were on ULT and that they were the same study subjects included in the group diagnosed according to the physiochemical criteria (HU-7/7) as according to the epidemiological criteria (HU-7/6) (Table S4, Supplementary Materials), which would further support the physiochemical criterion because it is closer to the SUA threshold that decides the ULT.
The main limitations of our study were the inability to determine causal relationships or to estimate incidence rates due to cross-sectional design, inter-interviewer variability, possible heterogeneity of the measurement and laboratory equipment, and the HU underdiagnoses due to people being excluded per protocol without SUA data. The values of the variables that were not reported in all study subjects were few, occurred at random, and were similar in the comparison groups, although this could imply a minimal confounding factor in the analysis of the difference between patients with and without HU. Results reporting associations between many factors or clinical conditions and the presence of HU should be interpreted as speculative and with caution, because multiple comparisons using OR and 95% CI could increase the risk of obtaining a statistically significant association by chance (familywise error or alpha-inflation phenomenon). Key strengths include a large sample of people between 18 to 102 years of age, recruited using a population-based method. Assessing the epidemiological magnitude of HU is essential to better plan prevention policies and optimize available health resources. The results reported herein are biologically plausible and consistent with the available scientific information, update the prevalence rates of HU according to the two diagnostic criteria most used by scientific societies, and help to better understand their clinical characteristics and the comorbidities and CKM factors associated with HU.

5. Conclusions

The prevalence rates of HU increase linearly with age in both men and women, and the rate higher in men regardless of age group. The associations of CKM factors with HU diagnosed according to the physiochemical criterion are more similar between men and women than those using epidemiological criteria. The results of our study support that that gender should not be a differentiating criterion for the HU diagnosis. A common SUA threshold level of 7 mg/dL for both genders would be more appropriate for HU diagnosis to unify further research on HU. The most important factors associated independently with HU according to the physiochemical criterion are hypertension, low eGFR, hypertriglyceridaemia, and alcoholism in both genders; albuminuria in women; and central obesity in men. Further studies would be needed to address HU as a risk factor for CKM syndrome.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm13164884/s1. Figure S1: Frequency according to SUA-groups; Table S1: Definitions and criteria of variables and clinical conditions; Table S2: Clinical characteristics of study population; Table S3: CKM factors and medical conditions in populations with and without hyperu-ricaemia according to HU-7/7 and HU-7/6 diagnostic criteria; Table S4: CKM factors and medical conditions in populations with HU-6 and HU-7; Table S5: Multivariate analysis of CKM factors and medical conditions for HU-7/7 and HU-7/6.

Author Contributions

Conceptualization, methodology, writing—review and editing: V.P.-C., A.R.-G., A.S.-C., E.A.-M. and C.E.-C.; writing—original draft preparation: V.P.-C., A.R.-G. and A.S.-C.; supervision: V.P.-C., A.R.-G., A.S.-C., E.A.-M. and C.E.-C.; project administration: A.R.-G., E.A.-M. and V.P.-C.; funding acquisition: A.R.-G. and E.A.-M. All authors have read and agreed to the published version of the manuscript.

Funding

Funding for the SIMETAP Study (Grant code: 05/2010RS) was approved in accordance with Order 472/2010, dated 16 September, of the Regional Ministry of Health (RMoH), approving regulatory bases and the call for grants for the year 2010 from the “Pedro Laín Entralgo” Agency for Training, Research, and Healthcare Studies of the Community of Madrid for the execution of research projects in the field of health outcomes in Primary Care. The researchers, members of the Scientific Committee, and principal investigator have not received any remuneration for participating in the SIMETAP study.

Institutional Review Board Statement

This study was carried out according to the guidelines of the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of Primary Care Health Service of the Community of Madrid on 8 November 2010 (Code 05/2010RS). Research Commission of the Deputy Management of Planning and Quality. Primary Care Management. Health Service of the Community of Madrid (SERMAS for its initials in Spanish).

Informed Consent Statement

The information obtained was treated with absolute confidentiality, respecting the principles of the Declaration of Helsinki. All study subjects invited to be included in the health system through their personalized identification system gave their authorization to the RMoH so that the information contained in their clinical history can also be used for research purposes, in accordance with data protection regulations. Participant data were anonymised after extraction.

Data Availability Statement

After deliberation, the data presented in this study are available upon request from the corresponding author. Data availability is restricted to participating researchers and, therefore, unavailable to the public.

Acknowledgments

We are grateful for the effort, dedication, and collaboration provided by of the following physicians who have participated in the SIMETAP Study Research Group: To the following researchers who have actively participated in the recruitment of subjects study: Abad Schilling C, Adrián Sanz M, Aguilera Reija P, Alcaraz Bethencourt A, Alonso Roca R, Álvarez Benedicto R, Arranz Martínez E, Arribas Álvaro P, Baltuille Aller MC, Barrios Rueda E, Benito Alonso E, Berbil Bautista ML, Blanco Canseco JM, Caballero Ramírez N, Cabello Igual P, Cabrera Vélez R, Calderín Morales MP, Capitán Caldas M, Casaseca Calvo TF, Cique Herráinz JA, Ciria de Pablo C, Chao Escuer P, Dávila Blázquez G, de la Peña Antón N, de Prado Prieto L, del Villar Redondo MJ, Delgado Rodríguez S, Díez Pérez MC, Durán Tejada MR, Escamilla Guijarro N, Escrivá Ferrairó RA, Fernández Vicente T, Fernández-Pacheco Vila D, Frías Vargas MJ, García Álvarez JC, García Fernández ME, García García Alcañiz MP, García Granado MD, García Pliego RA, García Redondo MR, García Villasur MP, Gómez Díaz E, Gómez Fernández O, González Escobar P, González-Posada Delgado JA, Gutiérrez Sánchez I, Hernández Beltrán MI, Hernández de Luna MC, Hernández López RM, Hidalgo Calleja Y, Holgado Catalán MS, Hombrados Gonzalo MP, Hueso Quesada R, Ibarra Sánchez AM, Iglesias Quintana JR, Íscar Valenzuela I, Iturmendi Martínez N, Javierre Miranda AP, López Uriarte B, Lorenzo Borda MS, Luna Ramírez S, Macho del Barrio AI, Magán Tapia P, Marañón Henrich N, Mariño Suárez JE, Martín Calle MC, Martín Fernández AI, Martínez Cid de Rivera E, Martínez Irazusta J, Migueláñez Valero A, Minguela Puras ME, Montero Costa A, Mora Casado C, Morales Cobos LE, Morales Chico MR, Moreno Fernández JC, Moreno Muñoz MS, Palacios Martínez D, Pascual Val T, Pérez Fernández M, Pérez Muñoz R, Plata Barajas MT, Pleite Raposo R, Prieto Marcos M, Quintana Gómez JL, Redondo de Pedro S, Redondo Sánchez M, Reguillo Díaz J, Remón Pérez B, Revilla Pascual E, Rey López AM, Ribot Catalá C, Rico Pérez MR, Rivera Teijido M, Rodríguez Cabanillas R, Rodríguez de Cossío A, Rodríguez De Mingo E, Rodríguez Rodríguez AO, Rosillo González A, Rubio Villar M, Ruiz Díaz L, Ruiz García A, Sánchez Calso A, Sánchez Herráiz M, Sánchez Ramos MC, Sanchidrián Fernández PL, Sandín de Vega E, Sanz Pozo B, Sanz Velasco C, Sarriá Sánchez MT, Simonaggio Stancampiano P, Tello Meco I, Vargas-Machuca Cabañero C, Velazco Zumarrán JL, Vieira Pascual MC, Zafra Urango C, Zamora Gómez MM, and Zarzuelo Martín N.

Conflicts of Interest

The authors declare no conflicts of interest. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

Abbreviations

AFatrial fibrillation
CKDchronic kidney disease
CKMcardiovascular–kidney–metabolic
CVDcardiovascular disease
CVRcardiovascular risk
DMdiabetes mellitus
eGFRestimated glomerular filtration rate
FLIfatty liver index
HFheart failure
HTGhypertriglyceridaemia
HTNarterial hypertension
HUhyperuricaemia
HU-6HU with SUA ≥ 6 mg/dL
HU-7HU with SUA ≥ 7 mg/dL
HU-7/6HU with SUA ≥ 7 mg/dL for men and ≥ 6.0 mg/dL for women
HU-7/7HU with SUA ≥ 7 mg/dL for both men and women
LDL-Clow-density lipoprotein cholesterol
MetSmetabolic syndrome
MSUmonosodium urate
SLDsteatotic liver disease
SUAserum uric acid
ULTurate-lowering drug therapy
WtHRwaist-to-height ratio

References

  1. Kellgren, J.H.; Jeffrey, M.R.; Ball, J.; Council for International Organizations of Medical Sciences. The Epidemiology of Chronic Rheumatism: [Proceedings of] A Symposium Organized by the Council for International Organizations of Medical Sciences Established under the Joint Auspices of UNESCo & WHO with Partial Support by Grants from the National Institute of Arthritis & Metabolic Diseases and the Arthritis & Rheumatism Foundation; Blackwell Scientific Publications: Oxford, UK, 1963; Available online: https://ci.nii.ac.jp/ncid/BA33063611 (accessed on 10 July 2024).
  2. Johnson, R.J.; Bakris, G.L.; Borghi, C.; Chonchol, M.B.; Feldman, D.; Lanaspa, M.A.; Merriman, T.R.; Moe, O.W.; Mount, D.B.; Lozada, L.G.S.; et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am. J. Kidney Dis. 2018, 71, 851–865. [Google Scholar] [CrossRef]
  3. Valsaraj, R.; Singh, A.K.; Gangopadhyay, K.K.; Ghoshdastidar, B.; Goyal, G.; Batin, M.; Mukherjee, D.; Sengupta, U.; Chatterjee, S.; Sengupta, N. Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement. Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 93–100. [Google Scholar] [CrossRef]
  4. Yamanaka, H.; Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: Second edition. Nucleosides Nucleotides Nucleic Acids 2011, 30, 1018–1029. [Google Scholar] [CrossRef] [PubMed]
  5. Khanna, D.; Fitzgerald, J.D.; Khanna, P.P.; Bae, S.; Singh, M.K.; Neogi, T.; Pillinger, M.H.; Merill, J.; Lee, S.; Prakash, S.; et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012, 64, 1431–1446. [Google Scholar] [CrossRef] [PubMed]
  6. Multidisciplinary Expert Task Force on Hyperuricemia and Related Diseases. Chinese Multidisciplinary Expert Consensus on the diagnosis and treatment of hyperuricemia and related diseases. Chin. Med J. 2017, 130, 2473–2488. [Google Scholar] [CrossRef]
  7. Chhana, A.; Lee, G.; Dalbeth, N. Factors influencing the crystallization of monosodium urate: A systematic literature review. BMC Musculoskelet. Disord. 2015, 16, 296. [Google Scholar] [CrossRef] [PubMed]
  8. Kimura, Y.; Tsukui, D.; Kono, H. Uric Acid in inflammation and the pathogenesis of atherosclerosis. Int. J. Mol. Sci. 2021, 22, 12394. [Google Scholar] [CrossRef] [PubMed]
  9. Lee, K.W.; Shin, D. Concurrent presence of high serum uric acid and inflammation is associated with increased incidence of type 2 diabetes mellitus in Korean adult population. Sci. Rep. 2022, 12, 11000. [Google Scholar] [CrossRef]
  10. Jeong, H.; Moon, J.E.; Jeon, C.H. Hyperuricemia is associated with an increased prevalence of metabolic syndrome in a general population and a decreased prevalence of diabetes in men. J. Rheum. Dis. 2020, 27, 247–260. [Google Scholar] [CrossRef]
  11. Sanchez-Lozada, L.G.; Rodriguez-Iturbe, B.; E Kelley, E.; Nakagawa, T.; Madero, M.; I Feig, D.; Borghi, C.; Piani, F.; Cara-Fuentes, G.; Bjornstad, P.; et al. Uric acid and hypertension: An update with recommendations. Am. J. Hypertens. 2020, 33, 583–594. [Google Scholar] [CrossRef]
  12. Wang, J.; Qin, T.; Chen, J.; Li, Y.; Wang, L.; Huang, H.; Li, J. Hyperuricemia and risk of incident hypertension: A systematic review and meta-analysis of observational studies. PLoS ONE 2014, 9, e114259. [Google Scholar] [CrossRef] [PubMed]
  13. Chrysant, S.G. Association of hyperuricemia with cardiovascular diseases: Current evidence. Hosp. Pract. 2023, 51, 54–63. [Google Scholar] [CrossRef] [PubMed]
  14. Casiglia, E.; Tikhonoff, V.; Virdis, A.; Masi, S.; Barbagallo, C.M.; Bombelli, M.; Bruno, B.; Cicero, A.F.; Cirillo, M.; Cirillo, P.; et al. Serum uric acid and fatal myocardial infarction: Detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. J. Hypertens. 2020, 38, 412–419. [Google Scholar] [CrossRef] [PubMed]
  15. Zhong, C.; Zhong, X.; Xu, T.; Xu, T.; Zhang, Y. Sex-Specific relationship between serum uric acid and risk of stroke: A dose-response me-ta-analysis of prospective studies. J. Am. Heart Assoc. 2017, 6, e005042. [Google Scholar] [CrossRef]
  16. Baker, J.F.; Schumacher, H.R.; Krishnan, E. Serum uric acid level and risk for peripheral arterial disease: Analysis of data from the multiple risk factor intervention trial. Angiology 2007, 58, 450–457. [Google Scholar] [CrossRef] [PubMed]
  17. Muiesan, M.L.; Salvetti, M.; Virdis, A.; Masi, S.; Casiglia, E.; Tikhonoff, V.; Barbagallo, C.M.; Bombelli, M.; Cicero, A.F.; Cirillo, M.; et al. Serum uric acid, predicts heart failure in a large Italian cohort: Search for a cut-off value the URic acid Right for heArt Health study. J. Hypertens. 2021, 39, 62–69. [Google Scholar] [CrossRef]
  18. Kuwabara, M.; Niwa, K.; Nishihara, S.; Nishi, Y.; Takahashi, O.; Kario, K.; Yamamoto, K.; Yamashita, T.; Hisatome, I. Hyperuricemia is an independent competing risk factor for atrial fibrillation. Int. J. Cardiol. 2017, 231, 137–142. [Google Scholar] [CrossRef]
  19. Ben-Dov, I.Z.; Kark, J.D. Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: The Jerusalem Lipid Research Clinic cohort study. Nephrol. Dial. Transplant. 2011, 26, 2558–2566. [Google Scholar] [CrossRef]
  20. Jakubiak, G.K.; Pawlas, N.; Morawiecka-Pietrzak, M.; Starzak, M.; Stanek, A.; Cieślar, G. Retrospective cross-sectional study of the relationship of thyroid volume and function with anthropometric measurements, body composition analysis parameters, and the diagnosis of metabolic syndrome in euthyroid people aged 18–65. Medicina 2024, 60, 1080. [Google Scholar] [CrossRef] [PubMed]
  21. Ndumele, C.E.; Rangaswami, J.; Chow, S.L.; Neeland, I.J.; Tuttle, K.R.; Khan, S.S.; Coresh, J.; Mathew, R.O.; Baker-Smith, C.M.; Carnethon, M.R.; et al. American Heart Association. Cardiovascular-kidney-metabolic health: A Presidential Advisory from the American Heart Association. Circulation 2023, 148, 1606–1635. [Google Scholar] [CrossRef]
  22. Alberti, K.G.M.M.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.C.; James, W.P.T.; Loria, C.M.; Smith, S.C., Jr. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation task force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120, 1640–1645. [Google Scholar] [CrossRef] [PubMed]
  23. Ruiz-García, A.; Arranz-Martínez, E.; García-Álvarez, J.C.; Morales-Cobos, L.E.; García-Fernández, M.E.; de la Peña-Antón, N.; Calle, M.C.M.; Costa, A.M.; Martínez, D.P.; Villasur, M.P.G.; et al. Population and methodology of the SIMETAP study: Prevalence of cardiovascular risk factors, cardiovascular diseases, and related metabolic diseases. Clin. E Investig. En Arter. 2018, 30, 197–208. [Google Scholar] [CrossRef]
  24. Roddy, E.; Zhang, W.; Doherty, M. The changing epidemiology of gout. Nat. Clin. Pract. Rheumatol. 2007, 3, 443–449. [Google Scholar] [CrossRef]
  25. Li, Q.; Li, X.; Wang, J.; Liu, H.; Kwong, J.S.-W.; Chen, H.; Li, L.; Chung, S.-C.; Shah, A.; Chen, Y.; et al. Diagnosis and treatment for hyperuricemia and gout: A systematic review of clinical practice guidelines and consensus statements. BMJ Open 2019, 9, e026677. [Google Scholar] [CrossRef] [PubMed]
  26. Zhu, Y.; Pandya, B.J.; Choi, H.K. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2001, 63, 3136–3141. [Google Scholar] [CrossRef] [PubMed]
  27. Trifirò, G.; Morabito, P.; Cavagna, L.; Ferrajolo, C.; Pecchioli, S.; Simonetti, M.; Bianchini, E.; Medea, G.; Cricelli, C.; Caputi, A.P.; et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: A nationwide population-based study. Ann. Rheum. Dis. 2013, 72, 694–700. [Google Scholar] [CrossRef] [PubMed]
  28. Chen, J.-H.; Yeh, W.-T.; Chuang, S.-Y.; Wu, Y.-Y.; Pan, W.-H. Gender-specific risk factors for incident gout: A prospective cohort study. Clin. Rheumatol. 2012, 31, 239–245. [Google Scholar] [CrossRef]
  29. Bardin, T.; Richette, P. Definition of hyperuricemia and gouty conditions. Curr. Opin. Rheumatol. 2014, 26, 186–191. [Google Scholar] [CrossRef]
  30. Higa, S.; Yoshida, M.; Shima, D.; Ii, Y.; Kitazaki, S.; Yamamoto, Y.; Fujimoto, Y. A retrospective, cross-sectional study on the prevalence of hyperuricemia using a Japanese healthcare database. Turk. J. Rheumatol. 2020, 35, 41–51. [Google Scholar] [CrossRef]
  31. Chen-Xu, M.; Yokose, C.; Rai, S.K.; Pillinger, M.H.; Choi, H.K. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019, 71, 991–999. [Google Scholar] [CrossRef]
  32. Maloberti, A.; Qualliu, E.; Occhi, L.; Sun, J.; Grasso, E.; Tognola, C.; Tavecchia, G.; Cartella, I.; Milani, M.; Vallerio, P.; et al. Hyperuricemia prevalence in healthy subjects and its relationship with cardiovascular target organ damage. Nutr. Metab. Cardiovasc. Dis. 2021, 31, 178–185. [Google Scholar] [CrossRef] [PubMed]
  33. Antelo-Pais, P.; Prieto-Díaz, M.; Micó-Pérez, R.M.; Pallarés-Carratalá, V.; Velilla-Zancada, S.; Polo-García, J.; Barquilla-García, A.; Ginel-Mendoza, L.; Segura-Fragoso, A.; Vitelli-Storelli, F.; et al. Prevalence of hyperuricemia and its association with cardiovascular risk factors and subclinical target organ damage. J. Clin. Med. 2023, 12, 50. [Google Scholar] [CrossRef] [PubMed]
  34. Huang, X.-B.; Zhang, W.-Q.; Tang, W.-W.; Liu, Y.; Ning, Y.; Huang, C.; Liu, J.-X.; Yi, Y.-J.; Xu, R.-H.; Wang, T.-D. Prevalence and associated factors of hyperuricemia among urban adults aged 35–79 years in southwestern China: A community-based cross-sectional study. Sci. Rep. 2020, 10, 15683. [Google Scholar] [CrossRef] [PubMed]
  35. Liu, C.-A.; Liu, T.; Ruan, G.-T.; Ge, Y.-Z.; Song, M.-M.; Xie, H.-L.; Lin, S.-Q.; Deng, L.; Zhang, H.-Y.; Zhang, Q.; et al. The relationship between fat distribution in central region and comorbidities in obese people: Based on NHANES 2011–2018. Front. Endocrinol. 2023, 14, 1114963. [Google Scholar] [CrossRef] [PubMed]
  36. Abdi, D.R.; Mohammadian, K.N.; Hosseinpour, A.; Asadi, S.; Ejtahed, H.S.; Qorbani, M. Waist to height ratio as a simple tool for predicting mortality: A systematic review and meta-analysis. Int. J. Obes. 2023, 47, 1286–1301. [Google Scholar] [CrossRef] [PubMed]
  37. Shirasawa, T.; Ochiai, H.; Yoshimoto, T.; Nagahama, S.; Watanabe, A.; Yoshida, R.; Kokaze, A. Cross-sectional study of associations between normal body weight with central obesity and hyperuricemia in Japan. BMC Endocr. Disord. 2020, 20, 2. [Google Scholar] [CrossRef]
  38. Romero-Saldaña, M.; Fuentes-Jiménez, F.J.; Vaquero-Abellán, M.; Álvarez-Fernández, C.; Aguilera-López, M.D.; Molina-Recio, G. Predictive capacity and cutoff value of waist-to-height ratio in the incidence of metabolic syndrome. Clin. Nurs. Res. 2019, 28, 676–691. [Google Scholar] [CrossRef]
  39. Gómez-Ambrosi, J.; Silva, C.; Catalán, V.; Rodríguez, A.; Galofré, J.C.; Escalada, J.; Valentí, V.; Rotellar, F.; Romero, S.; Ramírez, B.; et al. Clinical usefulness of a new equation for estimating body fat. Diabetes Care 2012, 35, 383–388. [Google Scholar] [CrossRef] [PubMed]
  40. Major, T.J.; Topless, R.K.; Dalbeth, N.; Merriman, T.R. Evaluation of the diet wide contribution to serum urate levels: Meta-analysis of population based cohorts. BMJ 2018, 363, k3951. [Google Scholar] [CrossRef]
  41. Kuwabara, M.; Borghi, C.; Cicero, A.F.; Hisatome, I.; Niwa, K.; Ohno, M.; Johnson, R.J.; Lanaspa, M.A. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. Int. J. Cardiol. 2018, 261, 183–188. [Google Scholar] [CrossRef]
  42. Zhang, M.-L.; Gao, Y.-X.; Wang, X.; Chang, H.; Huang, G.-W. Serum uric acid and appropriate cutoff value for prediction of metabolic syndrome among Chinese adults. J. Clin. Biochem. Nutr. 2013, 52, 38–42. [Google Scholar] [CrossRef] [PubMed]
  43. Hayden, M.R. Overview and new insights into the metabolic syndrome: Risk factors and emerging variables in the development of type 2 diabetes and cerebrocardiovascular disease. Medicina 2023, 59, 561. [Google Scholar] [CrossRef] [PubMed]
  44. Boccatonda, A.; Andreetto, L.; D’ardes, D.; Cocco, G.; Rossi, I.; Vicari, S.; Schiavone, C.; Cipollone, F.; Guagnano, M.T. From NAFLD to MAFLD: Definition, pathophysiological basis and cardiovascular implications. Biomedicines 2023, 11, 883. [Google Scholar] [CrossRef] [PubMed]
  45. Bedogni, G.; Bellentani, S.; Miglioli, L.; Masutti, F.; Passalacqua, M.; Castiglione, A.; Tiribelli, C. The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006, 6, 33. [Google Scholar] [CrossRef]
  46. Gagliardi, A.C.; Miname, M.H.; Santos, R.D. Uric acid: A marker of increased cardiovascular risk. Atherosclerosis 2009, 202, 11–17. [Google Scholar] [CrossRef] [PubMed]
  47. Krajčoviechová, A.; Wohlfahrt, P.; Bruthans, J.; Šulc, P.; Lánská, V.; Eremiášová, L.; Pudil, J.; Linhart, A.; Filipovský, J.; Mayer, O.; et al. Which serum uric acid levels are associated with increased cardiovascular risk in the general adult population? J. Clin. Hypertens. 2020, 22, 897–905. [Google Scholar] [CrossRef] [PubMed]
Jcm 13 04884 g001aJcm 13 04884 g001b
Figure 1. (A) Age-specific prevalence rates of HU-7/7; (B) Age-specific prevalence rates of HU-7/6. (A) HU-7/7: serum uric acid (SUA) ≥ 7.0 mg/dL (416 µmol/L) for both male and female. (B) HU-7/6: SUA ≥ 7.0 mg/dL (416 µmol/L) in males and ≥6.0 mg/dL (357 µmol/L) in females. n: number of cases; N: sample size; M: male; F: female; p: p-value of the difference in percentages (M vs. F).
Figure 1. (A) Age-specific prevalence rates of HU-7/7; (B) Age-specific prevalence rates of HU-7/6. (A) HU-7/7: serum uric acid (SUA) ≥ 7.0 mg/dL (416 µmol/L) for both male and female. (B) HU-7/6: SUA ≥ 7.0 mg/dL (416 µmol/L) in males and ≥6.0 mg/dL (357 µmol/L) in females. n: number of cases; N: sample size; M: male; F: female; p: p-value of the difference in percentages (M vs. F).
Jcm 13 04884 g001aJcm 13 04884 g001b
Jcm 13 04884 g002
Figure 2. CKM factors and medical conditions in populations with and without hyperuricaemia according to HU-7/7 and HU-7/6 diagnostic criteria. HU-7/7: hyperuricaemia with serum uric acid (SUA) ≥ 7.0 mg/dL (416 µmol/L) for both men and women; HU-7/6: SUA ≥ 7.0 mg/dL (416 µmol/L) for men and ≥6.0 mg/dL (357 µmol/L) for women; No. (%): cases number (percentage); OR: odds ratio; CI: confidence interval; p: p-value of the difference in percentage; a N = 683 (with HU-7/7), 5385 (without HU-7/7); b N = 916 (with HU-7/6), 5152 (without HU-7/6); ASCVD: atherosclerotic cardiovascular disease; BPLT: blood pressure-lowering drug therapy; CHD: coronary heart disease; CKD: chronic kidney disease; CKM: cardiovascular–kidney–metabolic; CUN-BAE: according to its acronym in Spanish, Clínica Universitaria de Navarra—Body Adiposity Estimator; eGFR: estimated glomerular filtration rate; FLI: fatty liver index; GLT: glycaemic-lowering drug therapy; HDL-C: high-density lipoprotein cholesterol; LLT: lipid-lowering drug therapy; PAD: peripheral arterial disease; CVR: cardiovascular risk; WtHR: waist-to-height ratio. The definitions of the CKM factors, comorbidities, and medical conditions are shown in Table S1 (Supplementary Materials).
Figure 2. CKM factors and medical conditions in populations with and without hyperuricaemia according to HU-7/7 and HU-7/6 diagnostic criteria. HU-7/7: hyperuricaemia with serum uric acid (SUA) ≥ 7.0 mg/dL (416 µmol/L) for both men and women; HU-7/6: SUA ≥ 7.0 mg/dL (416 µmol/L) for men and ≥6.0 mg/dL (357 µmol/L) for women; No. (%): cases number (percentage); OR: odds ratio; CI: confidence interval; p: p-value of the difference in percentage; a N = 683 (with HU-7/7), 5385 (without HU-7/7); b N = 916 (with HU-7/6), 5152 (without HU-7/6); ASCVD: atherosclerotic cardiovascular disease; BPLT: blood pressure-lowering drug therapy; CHD: coronary heart disease; CKD: chronic kidney disease; CKM: cardiovascular–kidney–metabolic; CUN-BAE: according to its acronym in Spanish, Clínica Universitaria de Navarra—Body Adiposity Estimator; eGFR: estimated glomerular filtration rate; FLI: fatty liver index; GLT: glycaemic-lowering drug therapy; HDL-C: high-density lipoprotein cholesterol; LLT: lipid-lowering drug therapy; PAD: peripheral arterial disease; CVR: cardiovascular risk; WtHR: waist-to-height ratio. The definitions of the CKM factors, comorbidities, and medical conditions are shown in Table S1 (Supplementary Materials).
Jcm 13 04884 g002
Jcm 13 04884 g003
Figure 3. Multivariate analysis results of medical conditions and CKM factors on hyperuricaemia. CI: confidence interval; CKM: cardiovascular–kidney–metabolic; eGFR: estimated glomerular filtration rate; HTG: hypertriglyceridaemia; HU-7/7: hyperuricaemia with serum uric acid (SUA) ≥ 7.0 mg/dL (416 µmol/L) for both men and women; HU-7/6: SUA ≥ 7.0 mg/dL (416 µmol/L) for men and ≥6.0 mg/dL (357 µmol/L) for women; HU-7: SUA ≥ 7.0 mg/dL (416 µmol/L); HU-6: ≥6.0 mg/dL (357 µmol/L); OR: odds ratio. The definitions of the CKM factors, comorbidities, and medical conditions are shown in Table S1 (Supplementary Materials).
Figure 3. Multivariate analysis results of medical conditions and CKM factors on hyperuricaemia. CI: confidence interval; CKM: cardiovascular–kidney–metabolic; eGFR: estimated glomerular filtration rate; HTG: hypertriglyceridaemia; HU-7/7: hyperuricaemia with serum uric acid (SUA) ≥ 7.0 mg/dL (416 µmol/L) for both men and women; HU-7/6: SUA ≥ 7.0 mg/dL (416 µmol/L) for men and ≥6.0 mg/dL (357 µmol/L) for women; HU-7: SUA ≥ 7.0 mg/dL (416 µmol/L); HU-6: ≥6.0 mg/dL (357 µmol/L); OR: odds ratio. The definitions of the CKM factors, comorbidities, and medical conditions are shown in Table S1 (Supplementary Materials).
Jcm 13 04884 g003
Jcm 13 04884 g004aJcm 13 04884 g004b
Figure 4. (A) Prevalence rates of independent factors associated with HU-7/7; (B) prevalence rates of independent factors associated with HU-7/6. HU-7/7: serum uric acid SUA) ≥ 7.0 mg/dL (416 µmol/L) for both sexes. HU-7/6: SUA ≥ 7.0 mg/dL in men and ≥6.0 mg/dL (357 µmol/L) in women. eGFR: estimated glomerular filtration rate; HTG: hypertriglyceridaemia. Definitions of the comorbidities and clinical conditions are shown in Table S1 (Supplementary Materials).
Figure 4. (A) Prevalence rates of independent factors associated with HU-7/7; (B) prevalence rates of independent factors associated with HU-7/6. HU-7/7: serum uric acid SUA) ≥ 7.0 mg/dL (416 µmol/L) for both sexes. HU-7/6: SUA ≥ 7.0 mg/dL in men and ≥6.0 mg/dL (357 µmol/L) in women. eGFR: estimated glomerular filtration rate; HTG: hypertriglyceridaemia. Definitions of the comorbidities and clinical conditions are shown in Table S1 (Supplementary Materials).
Jcm 13 04884 g004aJcm 13 04884 g004b
Table 1. Hyperuricaemia prevalence rates according to diagnostic criteria and sex and age groups.
Table 1. Hyperuricaemia prevalence rates according to diagnostic criteria and sex and age groups.
Crude Prevalence RatesAdjusted Prevalence Rates
Diagnostic CriteriaAge-Group
(Years)		Overall
% (95% CI)		Male
% (95% CI)		Female
% (95% CI)		pOverall
(%)		Male
(%)		Female
(%)
HU-7/7
HU-7/6		<405.6 (4.4–6.8)
6.6 (5.3–7.9)		12.1 (9.5–14.7)1.1 (0.4–1.7)
2.7 (1.6–3.8)		<0.0015.4
6.4		11.71.1
2.7
HU-7/7
HU-7/6		<507.6 (6.6–8.7)
8.9 (7.8–10.0)		15.6 (13.5–17.7)1.7 (1.0–2.3)
3.8 (2.8–4.8)		<0.0017.1
8.3		14.51.6
3.6
HU-7/7
HU-7/6		40–6912.1 (11.0–13.1)
15.2 (14.0–16.3)		21.7 (19.7–23.7)3.8 (3.0–4.7)
9.6 (8.3–10.9)		<0.00111.8
14.7		21.43.6
9.0
HU-7/7
HU-7/6		50–6913.1 (11.7–14.4)
17.0 (15.4–18.5)		22.7 (20.3–25.2)4.5 (3.4–5.7)
11.8 (10.1–13.6)		<0.00113.0
16.8		22.84.4
11.5
HU-7/7
HU-7/6		≥5014.0 (12.9–15.1)
19.5 (18.3–20.8)		23.4 (21.4–25.4)6.3 (5.3–7.3)
16.4 (14.8–18.0)		<0.00113.9
19.3		23.46.2
16.1
HU-7/7
HU-7/6		≥7015.5 (13.6–17.3)
23.9 (21.2–28.2)		24.7 (21.2–28.2)9.0 (7.1–10.9)
23.3 (20.5–26.2)		<0.001
0.543		15.5
23.9		24.79.1
23.4
HU-7/7
HU-7/6		≥1811.4 (10.6–12.2)
15.2 (14.3–16.1)		20.3 (18.9–21.8)4.4 (3.7–5.0)
11.2 (10.2–12.2)		<0.00110.2
13.4		18.43.8
9.6
HU-7/7: hyperuricaemia with serum uric acid (SUA) ≥ 7.0 mg/dL (416 µmol/L) for both male (M) and female (F); HU-7/6: hyperuricaemia with SUA ≥ 7.0 mg/dL (416 µmol/L) in men and ≥6.0 mg/dL (357 µmol/L) in women; CI: confidence interval; p: p-value of difference in percentages (M vs. F).
Table 2. Clinical characteristics of populations with and without hyperuricaemia.
Table 2. Clinical characteristics of populations with and without hyperuricaemia.
Male PopulationsFemale Populations
With HU-7
No. 581		Without HU-7
No. 2276		Cohen’s d
(95% CI)		With HU-7
No. 159		Without HU-7
No. 3473		Cohen’s d
(95% IC)		With HU-6
No. 406		Without HU-6
No. 3226		Cohen’s d
(95% CI)
Mean (SD)Mean (SD)Mean (SD)Mean (SD)Mean (SD)Mean (SD)
Age yr59.2 (15.5)54.3 (17.0)0.3
(0.2; 0.4) $$$		67.5 (15.8)54.5 (17.9)0.7
(0.6; 0.9) $$$		67.3 (15.4)53.5 (17.7)0.8
(0.7; 0.9) $$$
BMI kg/m229.5 (4.6)27.5 (4.4)0.5
(0.4; 0.5) $$$		31.4 (6.1)27.0 (5.5)0.8
(0.6; 1.0) $$$		31.1 (6.0)26.7 (5.3)0.8
(0.7; 0.9) $$$
WC cm102.4 (12.1)96.9 (12.5)0.4
(0.4; 0.5) $$$		100.6 (14.1)89.2 (13.9)0.8
(0.7; 1.0) $$$		99.6 (14.2)88.4 (13.6)0.8
(0.7; 0.9) $$$
WtHR0.60 (0.07)0.57 (0.08)0.4
(0.3; 0.5) $$$		0.65 (0.09)0.56 (0.10)0.9
(0.7; 1.1) $$$		0.64 (0.09)0.56 (0.09)0.9
(0.8; 1.0) $$$
CUN-BAE adiposity31.3 (5.6)28.3 (6.3)0.5
(0.4; 0.6) $$$		45.3 (5.9)39.0 (7.4)0.9
(0.7; 1.0) $$$		45.0 (5.9)38.6 (7.4)0.9
(0.8; 1.0) $$$
SBP mmHg126.8 (15.0)123.4 (13.7)0.2
(0.2; 0.3) $$$		129.3 (16.2)119.8 (16.1)0.6
(0.4; 0.8) $$$		129.5 (15.6)119.1 (15.9)0.7
(0.6; 0.8) $$$
DBP mmHg76.3 (10.0)74.5 (9.2)0.2
(0.1; 0.3) $$$		75.5 (9.4)72.0 (9.9)0.4
(0.2; 0.5) $$$		75.7 (9.6)71.7 (9.8)0.4
(0.3; 0.5) $$$
FPG mg/dL a100.3 (22.6)99.5 (29.6)0.0
(−0.1; 0.1) NS		101.0 (24.0)92.7 (23.2)0.4
(0.2; 0.5) $$$		101.3 (25.3)92.0 (22.8)0.4
(0.3; 0.5) $$$
HbA1c % b #5.74 (0.75)5.70 (0.97)0.0
(−0.1; 0.1) NS		5.99 (0.93)5.55 (0.85)0.5
(0.4; 0.7) $$$		5.95 (0.93)5.52 (0.83)0.5
(0.4; 0.6) $$$
TC mg/dL c191.2 (39.9)187.5 (38.8)0.1
(0.0; 0.2) $		199.8 (42.2)196.3 (39.1)0.1
(−0.1; 0.3) NS		198.8 (42.1)196.1 (38.9)0.1
(0.0; 0.2) NS
HDL-C mg/dL c47.1 (12.0)49.8 (12.7)−0.2
(−0.3; −0.1) $$$		53.8 (13.4)59.5 (14.7)−0.4
(−0.6; −0.2) $$$		56.0 (14.2)59.7 (14.7)−0.3
(−0.4; −0.2) $$$
Non-HDL-C mg/dL c144.1 (39.1)137.7 (38.7)0.2
(0.1; 0.3) $$$		146.0 (38.4)136.7 (38.1)0.2
(0.1; 0.4) $$		142.9 (40.5)136.4 (37.8)0.2
(0.1; 0.3) $$
TG mg/dL d162.3 (132.0)129.1 (90.5)0.3
(0.2; 0.4) $$$		149.8 (108.5)106.6 (60.6)0.7
(0.5; 0.8)		144.6 (93.2)103.9 (57.8)0.7
(0.6; 0.8) $$$
SUA mg/dL e7.61 (1.16)5.21 (1.02)2.0
(1.9; 2.1) $$$		7.52 (1.02)4.25 (1.05)3.1
(3.0; 3.3) $$$		6.80 (0.89)4.09 (0.91)3.0
(2.9; 3.1) $$$
Creatinine mg/dL f1.07 (0.38)0.93 (0.26)0.5
(0.4; 0.6) $$$		0.99 (0.52)0.7 (0.23)1.0
(0.8; 1.2) $$$		0.92 (0.48)0.73 (0.21)0.8
(0.7; 0.9) $$$
eGFR mL/min/1.73 m280.7 (21.6)92.0 (18.5)−0.6
(−0.7; −0.5) $$$		68.8 (25.1)92.2 (20.3)−1.1
(−1.3; −1.0) $$$		72.5 (24.3)93.5 (19.4)−1.1
(−1.2; −1.0) $$$
uACR mg/g g34.1 (111.3)17.3 (69.2)0.2
(0.1; 0.3) $$$		33.7 (81.6)12.2 (36.1)0.6
(0.4; 0.7) $$$		25.4 (70.1)11.6 (33.3)0.4
(0.3; 0.5) $$$
HU-7 (hyperuricaemia): serum uric acid (SUA) ≥ 7.0 mg/dL (416 µmol/L). HU-6: SUA ≥ 6.0 mg/dL (357 µmol/L). SD: standard deviation; Cohen’s d; standardised mean difference (effect size according to d-values: 0.2 small; 0.5 medium; 0.8 large); CI: confidence interval; $$$: p-value of the difference in means < 0.001; $$: p < 0.01; $: p < 0.05; NS: non-significant. The definitions of the variables are shown in Table S1 (Supplementary Materials). BMI: body mass index; CUN-BAE-adiposity: adiposity or body fat index CUN-BAE (according to its acronym in Spanish, Clínica Universitaria de Navarra—Body Adiposity Estimator); DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; HbA1c: glycated haemoglobin A1c (# No. with vs. without HU-7 [men]: 482 vs. 1845; No. with vs. without HU-7 [women]: 132 vs. 2719; No. with vs. without HU-6 [women]: 347 vs. 2504); HDL-C: high-density lipoprotein cholesterol; SBP: systolic blood pressure; TC: total cholesterol; TG: triglycerides; uACR: urine albumin–creatinine ratio; WC: waist circumference; WtHR: waist-to-height ratio. a To convert from mg/dL to mmol/L, multiply by 0.05556; b to convert from % (DCCT) to mmol/mol (IFCC), subtract 2.15 and multiply by 10.929; c to convert from mg/dL to mmol/L, multiply by 0.02586; d to convert from mg/dL to mmol/L, multiply by 0.01129; e to convert from mg/dL to mmol/L, multiply by 0.05948; f to convert from mg/dL to mmol/L, multiply by 0.08842; g to convert from mg/g to mg/mmol, multiply by 0.01131.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ruiz-García, A.; Serrano-Cumplido, A.; Arranz-Martínez, E.; Escobar-Cervantes, C.; Pallarés-Carratalá, V. Hyperuricaemia Prevalence Rates According to Their Physiochemical and Epidemiological Diagnostic Criteria and Their Associations with Cardio-Renal-Metabolic Factors: SIMETAP-HU Study. J. Clin. Med. 2024, 13, 4884. https://doi.org/10.3390/jcm13164884

AMA Style

Ruiz-García A, Serrano-Cumplido A, Arranz-Martínez E, Escobar-Cervantes C, Pallarés-Carratalá V. Hyperuricaemia Prevalence Rates According to Their Physiochemical and Epidemiological Diagnostic Criteria and Their Associations with Cardio-Renal-Metabolic Factors: SIMETAP-HU Study. Journal of Clinical Medicine. 2024; 13(16):4884. https://doi.org/10.3390/jcm13164884

Chicago/Turabian Style

Ruiz-García, Antonio, Adalberto Serrano-Cumplido, Ezequiel Arranz-Martínez, Carlos Escobar-Cervantes, and Vicente Pallarés-Carratalá. 2024. "Hyperuricaemia Prevalence Rates According to Their Physiochemical and Epidemiological Diagnostic Criteria and Their Associations with Cardio-Renal-Metabolic Factors: SIMETAP-HU Study" Journal of Clinical Medicine 13, no. 16: 4884. https://doi.org/10.3390/jcm13164884

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop